Orchid Pharma has the GF Score of 66, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Orchid Pharma
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Orchid Pharma (LUX:ORCHP) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Orchid Pharma GF Score Related Terms
LUX:ORCHP vs ZTS, UTHR: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchid Pharma GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's GF Score distribution charts can be found below:
* The bar in red indicates where Orchid Pharma's GF Score falls into.
Orchid Pharma (LUX:ORCHP) has a GF Score of 66 as of Jul. 05, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Orchid Pharma and its competitors. This is near median its historical median of 64.00. Over the past decade, Orchid Pharma's GF Score has ranged from 10.00 to 84.00.
Is Orchid Pharma's GF Score too high?
Orchid Pharma's current GF Score of 66 is near median its 10-year median of 64.00. Over the past 10 years, this metric has ranged from a low of 10.00 to a high of 84.00. Overall, Orchid Pharma has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's GF Score compare to ZTS and UTHR?
Orchid Pharma's GF Score of 66 can be compared against companies in the Drug Manufacturers industry. Historically, Orchid Pharma's own GF Score has ranged from 10.00 to 84.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Orchid Pharma and its competitors. Orchid Pharma's current GF Score is 66, which is near median its own 10-year median of 64.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (LUX:ORCHP) has a current GF Score of 66. The stock's GF Value™ is $4.68, compared to a current price of $5.45 — trading 16.5% above its estimated fair value. The current GF Score is 66, which is near median its 10-year median of 64.00. Orchid Pharma's overall GF Score™ is 66/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current GF Score is 66 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?
Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued.
The current stock price of $5.45 is trading 16.5% above its estimated GF Value™ of $4.68.
Key valuation signals for LUX:ORCHP:
GF Score: 66 (near median its 10-year median of 64.00)
GF Value™: $4.68 vs. price of $5.45 (16.5% above fair value)
No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
66GF Score
Get the complete analysis for LUX:ORCHP
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ORCHP has been successfully added to your 